Alx Oncology Holdings (ALXO) Equity Ratio (2019 - 2026)

Alx Oncology Holdings' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.85 for Q1 2026.

• In Q1 2026, Equity Ratio rose 16.21% year-over-year to 0.85; the TTM figure through Mar 2026 stood at 0.85 (up 16.21% YoY), while the FY2025 annual figure was 0.44, down 42.77% from the prior year.
• Equity Ratio came in at 0.85 for Q1 2026 at Alx Oncology Holdings, up from 0.44 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.94 in Q1 2022 to a low of 0.44 in Q4 2025.
• A 5-year average of 0.77 and a median of 0.77 in 2024 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio slumped 42.77% in 2025 and rose 16.21% in 2026, its largest moves.
• Alx Oncology Holdings' Equity Ratio stood at 0.86 in 2022, then dropped by 9.01% to 0.78 in 2023, then fell by 1.7% to 0.77 in 2024, then plunged by 42.77% to 0.44 in 2025, then soared by 92.88% to 0.85 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.85, 0.44, and 0.54 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison